Blaze Bioscience aims to launch new pediatric brain cancer study with scorpion venom

Blaze Bioscience has scooped up $4 million of a $5 million round to maintain its momentum to hopefully initiate a Pivotal clinical study on pediatric brain cancer later this year. Blaze is the company behind Tumor Paint, a synthetic scorpion venom that binds to cancer cells and glows under near-infrared light. The Puget Sound Business Journal featured Blaze last year as an Innovator of the Month. At the time, the company had raised $30 million since its founding, and Tum or Paint had been used…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news